Medytox CEO Jung Hyun-ho is slated to meet with executives at Allergan to discuss the start of phase 3 clinical trials of its liquid-type botulinum toxin Innotox this week, according to local news reports Tuesday.
Medytox and Allergan struck a license partnership in 2013, when the Seoul-based company sold the global development and commercialization rights to Innotox to Allergan for $360 million.
Jung’s recent visit to the US is aimed at cementing a concrete timetable for the US clinical trials of Innotox, according to local reports.
 |
Medytox CEO Jung Hyun-ho (Park Hyun-koo/The Korea Herald) |
Allergan announced in its 2016 second quarter earnings report that it would begin the third-phase trials of Innotox in early 2017. However it is yet to begin the trials due to scale-up production issues with Medytox. Since then, Allergan had not publicized further plans for Innotox, fueling investor concerns.
A Medytox official told a local news outlet that the given production issues have been resolved and that it “expects Allergan to begin the phase 3 trials of Innotox by the end of this year.”
If Allergan does decide to carry out the final-stage trials of Innotox, the move is expected to lend a major revenue boost to Medytox which will produce and sell the liquid-injectable antiwrinkle fillers to be used in the trials to its global partner.
A Medytox spokesperson could not be reached for comment when contacted by The Korea Herald on Tuesday.
By Sohn Ji-young (
jys@heraldcorp.com)
